Autolus

Autolus, a commercial-stage biopharmaceutical company founded in 2014, specializes in developing and delivering next-generation programmed T cell therapies for cancer and autoimmune diseases. Based in London, United Kingdom, Autolus operates within the Pharmaceuticals and Healthcare sectors, utilizing a proprietary suite of modular T cell programming technologies. These technologies engineer therapies for precise targeting, control, and enhanced activity against target cells, aiming to overcome disease mechanisms.

The company's flagship product, AUCATZYL (obecabtagene autoleucel, obe-cel), is an FDA-approved CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, with ongoing regulatory review in Europe. Autolus also maintains a pipeline of candidates for hematological malignancies, solid tumors, and autoimmune conditions, including programs targeting systemic lupus erythematosus, multiple myeloma, neuroblastoma, and acute myeloid leukemia. Operating with 500-1,000 employees across two locations in the United States and United Kingdom, the company supports its commercial and clinical-stage programs with dedicated manufacturing and research capabilities. Meet Autolus's team to learn more about their scientific and operational expertise.

With a reported revenue of $92.6M, Autolus has secured significant funding, including a $250 million private equity round in November 2021 and other substantial placements. This financial backing supports its ambitious development and commercialization efforts. The company's NASDAQ ticker is AUTL. Autolus competes in a dynamic market with companies like Adaptimmune Therapeutics and Orchard Therapeutics, focusing on advanced cell and gene therapies. Explore financial highlights for detailed insights into their fiscal performance and investment rounds.